As of November 6, 2020, KBL Merger Corp. IV was acquired by 180 Life Sciences Corp., in a reverse merger transaction. KBL Merger Corp. IV is a private equity firm specializing in acquisition, buyout, PIPES and secondaries investments. The firm seeks to invest in healthcare or the healthcare-related wellness industry. In healthcare services the firm seeks to invest in outpatient care, physician practices, behavioral health and payor services. In pharma services the firm seeks to invest in outsourced services, contract research and generics / OTC. In health IT the firm seeks to invest in EMR / HER, revnue cycle management, telemedicine and care management. In minimal reimbursement risk the firm focuses on retail healthcare, wellness and preventative care. In devices and diagnostics the firm focuses on medical devices, diagnostics, genetic testing and lab tools. The firm typically invests in firms located in the United States. The firm seeks to invest in firms with valuation between $200 million to $700 million and EBITDA between $20 million to $70 million. The firms invest in firms with enterprise value $200 million to $700 million. The firm seeks to take majority stakes. KBL Merger Corp. IV was founded in 2016 and is New York, New York with an additional office in Newark, Delaware.